Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study
Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients. Objective: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort study. Settings:...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Multidisciplinary Digital Publishing Institute
2022
|
| Online Access: | https://hdl.handle.net/1721.1/133188.2 |
| _version_ | 1811087619974496256 |
|---|---|
| author | Alcala-Diaz, Juan F. Limia-Perez, Laura Gomez-Huelgas, Ricardo Martin-Escalante, Maria D. Cortes-Rodriguez, Begoña Zambrana-Garcia, Jose L. Entrenas-Castillo, Marta Perez-Caballero, Ana I. López-Carmona, Maria D. Garcia-Alegria, Javier Lozano Rodríguez-Mancheño, Aquiles Arenas-de Larriva, Maria del Sol Pérez-Belmonte, Luis M. Jungreis, Irwin Bouillon, Roger Quesada-Gomez, Jose Manual Lopez-Miranda, Jose |
| author2 | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory |
| author_facet | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory Alcala-Diaz, Juan F. Limia-Perez, Laura Gomez-Huelgas, Ricardo Martin-Escalante, Maria D. Cortes-Rodriguez, Begoña Zambrana-Garcia, Jose L. Entrenas-Castillo, Marta Perez-Caballero, Ana I. López-Carmona, Maria D. Garcia-Alegria, Javier Lozano Rodríguez-Mancheño, Aquiles Arenas-de Larriva, Maria del Sol Pérez-Belmonte, Luis M. Jungreis, Irwin Bouillon, Roger Quesada-Gomez, Jose Manual Lopez-Miranda, Jose |
| author_sort | Alcala-Diaz, Juan F. |
| collection | MIT |
| description | Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients. Objective: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort study. Settings: Hospitalized care. Patients: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Intervention: Patients received calcifediol (25-hydroxyvitamin D<sub>3</sub>) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. Main Outcome Measure: In-hospital mortality during the first 30 days after admission. Results: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; <i>p</i> < 0.01). Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80). Conclusion: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings. |
| first_indexed | 2024-09-23T13:49:21Z |
| format | Article |
| id | mit-1721.1/133188.2 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T13:49:21Z |
| publishDate | 2022 |
| publisher | Multidisciplinary Digital Publishing Institute |
| record_format | dspace |
| spelling | mit-1721.1/133188.22024-02-26T21:24:42Z Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study Alcala-Diaz, Juan F. Limia-Perez, Laura Gomez-Huelgas, Ricardo Martin-Escalante, Maria D. Cortes-Rodriguez, Begoña Zambrana-Garcia, Jose L. Entrenas-Castillo, Marta Perez-Caballero, Ana I. López-Carmona, Maria D. Garcia-Alegria, Javier Lozano Rodríguez-Mancheño, Aquiles Arenas-de Larriva, Maria del Sol Pérez-Belmonte, Luis M. Jungreis, Irwin Bouillon, Roger Quesada-Gomez, Jose Manual Lopez-Miranda, Jose Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients. Objective: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort study. Settings: Hospitalized care. Patients: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Intervention: Patients received calcifediol (25-hydroxyvitamin D<sub>3</sub>) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. Main Outcome Measure: In-hospital mortality during the first 30 days after admission. Results: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; <i>p</i> < 0.01). Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80). Conclusion: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings. 2022-01-21T16:24:23Z 2021-10-27T17:56:25Z 2022-01-21T16:24:23Z 2021-05 2021-05 2021-05-24T15:07:19Z Article http://purl.org/eprint/type/JournalArticle 2072-6643 https://hdl.handle.net/1721.1/133188.2 Nutrients 13 (6): 1760 (2021) http://dx.doi.org/10.3390/nu13061760 Nutrients Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ application/octet-stream Multidisciplinary Digital Publishing Institute Multidisciplinary Digital Publishing Institute |
| spellingShingle | Alcala-Diaz, Juan F. Limia-Perez, Laura Gomez-Huelgas, Ricardo Martin-Escalante, Maria D. Cortes-Rodriguez, Begoña Zambrana-Garcia, Jose L. Entrenas-Castillo, Marta Perez-Caballero, Ana I. López-Carmona, Maria D. Garcia-Alegria, Javier Lozano Rodríguez-Mancheño, Aquiles Arenas-de Larriva, Maria del Sol Pérez-Belmonte, Luis M. Jungreis, Irwin Bouillon, Roger Quesada-Gomez, Jose Manual Lopez-Miranda, Jose Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study |
| title | Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study |
| title_full | Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study |
| title_fullStr | Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study |
| title_full_unstemmed | Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study |
| title_short | Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study |
| title_sort | calcifediol treatment and hospital mortality due to covid 19 a cohort study |
| url | https://hdl.handle.net/1721.1/133188.2 |
| work_keys_str_mv | AT alcaladiazjuanf calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT limiaperezlaura calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT gomezhuelgasricardo calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT martinescalantemariad calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT cortesrodriguezbegona calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT zambranagarciajosel calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT entrenascastillomarta calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT perezcaballeroanai calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT lopezcarmonamariad calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT garciaalegriajavier calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT lozanorodriguezmanchenoaquiles calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT arenasdelarrivamariadelsol calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT perezbelmonteluism calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT jungreisirwin calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT bouillonroger calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT quesadagomezjosemanual calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy AT lopezmirandajose calcifedioltreatmentandhospitalmortalityduetocovid19acohortstudy |